It is estimated more than 500,000 individuals succumb to end stage renal disease annually in sub-Saharan Africa with an additional 50 million people suffering from pre-dialysis chronic kidney disease. Advanced genome-based analysis strategies, such as Mapping by Admixture Linkage Disequilibrium (MALD) in African Americans, have identified a strong association between single gene variants (e.g., MYH9 and AP0L1) and kidney disease. In addition, nearly 20 genetic variants have been linked to childhood onset nephrotic syndrome. Most of these genetic advances in elucidating the etiology of kidney disease have occurred outside sub-Saharan Africa where there is a shortage of genetic experts and the infrastructure for human genomic research is as sparse as the Sahara Desert itself. In this application, we propose to rapidly increase the capacity to conduct genomic studies of kidney disease in sub-Saharan Africa through a collaborative research network comprised of investigators based at 10 institutions in five African countries - pop. 362 million (Ethiopia, Ghana, Kenya, Nigeria and South Africa) and four North American institutions. The Network will accomplish the following seven objectives: (1) phenotype 8,000 kidney disease cases and controls (1:1);(2) conduct four genetic research projects addressing single gene mutation kidney disorders in affected families, genetic variants of single genes associated with kidney diseases in the populations and genome wide association studies;(3) establish two low-capital intensity, rugged and sustainable genomics research laboratories in Africa;(4) implement a customized six-track training and career development plan for African-based genomic researchers;(5) establish and maintain a Network-wide biospecimen repository that will harmonize seamlessly with the H3Africa Biorepository Grants (RFA-RM-11-011);(6) establish and maintain a Network-wide data management and bioinformatics facility that will effectively integrate with the H3Africa Bioinformatics Network (RFA-RM-11-010) and (7) cooperate and coordinate the activities of this Network with the H3Africa Consortium and the NIH Program Scientists/Staff. This application is submitted by the University of Ghana with substantial institutional support from the University of Michigan.
More than 500,000 people die from kidney failure annually in sub-Saharan Africa. Recent advances in genomic science suggest a strong genetic component to the excess risk of kidney failure in African Americans who have 3- to 4-fold greater risk of kidney disease compared to Whites. The projects in this application will enable African-based scientists to conduct genetic research to elucidate the hereditary and environmental factors that predisposes people in sub-Saharan Africa to a high risk of kidney failure.
|Osafo, Charlotte; Raji, Yemi R; Olanrewaju, Timothy et al. (2016) Genomic approaches to the burden of kidney disease in Sub-Saharan Africa: the Human Heredity and Health in Africa (H3Africa) Kidney Disease Research Network. Kidney Int 90:2-5|
|Peprah, Emmanuel; Wiley, Ken; Troyer, Jennifer et al. (2016) Building a Platform to Enable NCD Research to Address Population Health in Africa: CVD Working Group Discussion at the Sixth H3Africa Consortium Meeting in Zambia. Glob Heart 11:165-70|
|Osafo, Charlotte; Raji, Yemi Raheem; Burke, David et al. (2015) Human Heredity and Health (H3) in Africa Kidney Disease Research Network: A Focus on Methods in Sub-Saharan Africa. Clin J Am Soc Nephrol 10:2279-87|
|Wright, Galen E B; Adeyemo, Adebowale A; Tiffin, Nicki (2014) Informed consent and ethical re-use of African genomic data. Hum Genomics 8:18|
|(2014) Research capacity. Enabling the genomic revolution in Africa. Science 344:1346-8|
|Owolabi, Mayowa O; Mensah, George A; Kimmel, Paul L et al. (2014) Understanding the rise in cardiovascular diseases in Africa: harmonising H3Africa genomic epidemiological teams and tools. Cardiovasc J Afr 25:134-6|
|Ojo, Akinlolu (2014) Addressing the global burden of chronic kidney disease through clinical and translational research. Trans Am Clin Climatol Assoc 125:229-43; discussion 243-6|